Bli medlem
Bli medlem

Du är här


Xvivo Perfusion: XPS™ to Switzerland

The University Hospital in Lausanne CHUV, Switzerland has decided to
acquire the Xvivo Perfusion system, XPS™. This is the first XPS™ to a
Swiss hospital. It is estimated that delivery and installation of the
XPS™ will take place in March 2016.

The XPS™ is the only system on the market for Ex Vivo Lung Perfusion
(EVLP) that is approved on all major markets, including US approval
by the FDA. The XPS™ system gives the user the flexibility to perform
evaluation of lungs for transplantation using a standardized and
simplified procedure. The XPS™ has achieved good clinical results
when used at leading clinics in the USA and Europe. In Europe, five
clinics will have the XPS™-system, whereof one clinic in

"We are very pleased that the clinic in Lausanne, which is one of the
most important clinics in Switzerland, now starts to use XPS™ to
facilitate EVLP," says Magnus Nilsson, CEO of XVIVO Perfusion.

January 29, 2016
XVIVO Perfusion AB (publ)

For further information please contact:
Christoffer Rosenblad, CFO, +1 720 616 2101,

For further information on XVIVO Perfusion's business, please refer to
the company's website,

The information was submitted for publication on January 29, 2016 at
8:30 a.m.

This is a translation of the Swedish version of the press release.
When in doubt, the Swedish wording prevails.


XVIVO Perfusion AB is a medical technology company which develops
solutions and systems for assessing and preserving organs outside the
body and for selecting usable organs and maintaining them in optimal
condition pending transplantation.

The company is headquartered in Gothenburg, Sweden, and has one office
in the USA. The XVIVO share is listed on NASDAQ OMX First North and
has the ticker symbol XVIVO. More information can be found on the
website The Certified Adviser is Redeye,


XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate
identity number 556561-0424.

Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: Website:

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.